Related Experiment Videos
Cancer epigenetics
1Département de pharmacology, Université de Montréal, Centre de recherché, Hôpital Sainte-Justine, 3175 Côte Ste-Catherine Montreal, Que H3T 1C5, Canada. richard.l.momparler@umontreal.ca
Oncogene
|October 7, 2003
Summary
Aberrant DNA methylation and histone deacetylation silence tumor suppressor genes. Inhibitors like 5-azadeoxycytidine (5AZA) and HDAC inhibitors can reverse this, offering potential epigenetic cancer therapy.
Area of Science:
- Epigenetics
- Cancer Biology
- Molecular Oncology
Background:
- Aberrant DNA methylation silences tumor suppressor genes, crucial for preventing cancer.
- Histone deacetylation compacts chromatin, repressing gene expression and promoting tumor growth.
- Cross-talk between DNA methylation and histone deacetylation creates a transcriptionally repressive complex.
Purpose of the Study:
- To investigate the therapeutic potential of targeting epigenetic modifications in cancer.
- To explore the synergistic effects of DNA methylation and histone deacetylase inhibitors.
Main Methods:
- Utilizing inhibitors of DNA methylation, such as 5-azadeoxycytidine (5AZA).
- Employing inhibitors of histone deacetylase (HDAC).
- Investigating the combined effects of 5AZA and HDAC inhibitors on gene expression and tumor cells.
Main Results:
- 5AZA and HDAC inhibitors can reverse epigenetic silencing of tumor suppressor genes.
- Combined treatment leads to synergistic reactivation of these genes.
- Enhanced antineoplastic effects observed against tumor cells.
Conclusions:
- Epigenetic modifications, DNA methylation and histone deacetylation, are key targets for cancer therapy.
- Combined inhibition of these pathways offers a promising novel epigenetic therapy strategy.
- Further investigation into combined 5AZA and HDAC inhibitor therapy is warranted.